The short version of lyophilized powder fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-26 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
An overabundance of 5-HT3 receptors is reported in cocaine-conditioned rats, though 5-HT3's role is unclear. The 5-HT2 receptor (particularly the subtypes 5-HT2A, 5-HT2B and 5-HT2C) are involved in the locomotor-activating effects of cocaine. Cocaine has been demonstrated to bind as to directly stabilize the DAT transporter on the open outward-facing conformation. Further, cocaine binds in such a way as to inhibit a hydrogen bond innate to DAT. Cocaine's binding properties are such that it attaches so this hydrogen bond will not form and is blocked from formation due to the tightly locked orientation of the cocaine molecule. Research studies have suggested that the affinity for the transporter is not what is involved in the habituation of the substance so much as the conformation and binding properties to where and how on the transporter the molecule binds. Conflicting findings have challenged the widely accepted view that cocaine functions solely as a reuptake inhibitor. To induce euphoria an intravenous dose of 0.3-0.6 mg/kg of cocaine is required, which blocks 66-70% of DAT in the brain. Re-administering cocaine beyond this threshold does not significantly increase DAT occupancy but still results in an increase of euphoria which cannot be explained by reuptake inhibition alone. This discrepancy is not shared with other dopamine reuptake inhibitors like bupropion, sibutramine, mazindol or tesofensine, which have similar or higher potencies than cocaine as dopamine reuptake inhibitors.
Both lancelets and lampreys have a primitive but functional interferon system that responds to their versions of interferons by upregulating gene similar to the well-known interferon-stimulated genes (LSGs) of land animals. The lamprey interferon receptor has also been identified as a heterodimer of the cytokine receptor family B (CRFB) family, much like in jawed vertebrates. By comparing the genome organizations of jawed fish, jawless fish, and lancelet, it was found that interferons arose by a duplication of interleukin 10 in a chordate ancestor to the vertebrates and the lancelets. By the time the bony fish (e.g. teleosts, tetrapods including humans) diverged from the cartilaginous fish (e.g. sharks), the duplication and specialization of interferon into types I, II (gamma), III (lambda), and IV had been complete. (This is known because types I, II, IV have been found in tetrapods, teleosts, and sharks, and that type III has been found in tetrapods and sharks.) Mammals, actually amniotes in general, are unlike the rest of the animal kingdom in that most of their type I IFNs are intronless, and are placed in a position not colinear with the other vertebrates. This is because the original type I IFN gene was copied in an intronless form (possibly by a retrotransposon acting on mRNA) to a new location between HACD4 and MTAP in a common ancestor of the amniotes, followed by a loss of the ancestral version.
=== Borderline personality disorder === Main section: § Borderline personality disorder Recent epigenetic findings suggest that KOR antagonists, which block the hyperactive KOR system, might be a viable pharmacological approach for borderline personality disorder (BPD) treatment, particularly for anhedonia, suicidality, and dissociative symptoms. Current early evidence supports the efficacy of naltrexone and nalmefene in reducing suicidal ideation, non-suicidal self-injury, binge eating, and dissociation in patients with BPD.
In the absence of a gut compartment, input can be made directly in the liver. However, in that case local metabolism in the gut may not be correctly described. The case of approximately continuous absorption (e.g. via drinking water) can be modeled by a zero-order absorption rate (here Ring in units of mass over time):
Sources: en.wikipedia.org
If it starts the mass killing of elements of the army, including officers who were not involved in the coup, this may trigger a "counter-coup" by soldiers who are afraid they will be next. To prevent such a desperate counter-coup that may be more successful than the initial attempt, governments usually resort to firing prominent officers and replacing them with loyalists instead. Notable counter-coups include the Ottoman countercoup of 1909, the 1960 Laotian counter-coup, the Indonesian mass killings of 1965–66, the 1966 Nigerian counter-coup, the 1967 Greek counter-coup, 1971 Sudanese counter-coup, and the coup d'état of December Twelfth in South Korea. A 2017 study finds that the use of state broadcasting by the putschist regime after Mali's 2012 coup did not elevate explicit approval for the regime.
Proto-oncogene tyrosine-protein kinase Fyn (p59-FYN, Slk, Syn, MGC45350, Gene ID 2534) is an enzyme that in humans is encoded by the FYN gene. Fyn is a 59-kDa member of the Src family of kinases typically associated with T-cell and neuronal signaling in development and normal cell physiology. Disruptions in these signaling pathways often have implications in the formation of a variety of cancers. By definition as a proto-oncogene, Fyn codes for proteins that help regulate cell growth. Changes in its DNA sequence transform it into an oncogene that leads to the formation of a different protein with implications for normal cell regulation. Fyn is a member of the protein-tyrosine kinase oncogene family. It encodes a membrane-associated tyrosine kinase that has been implicated in the control of cell growth. The protein associates with the p85 subunit of phosphatidylinositol 3-kinase and interacts with the fyn-binding protein. Alternatively spliced transcript variants encoding distinct isoforms exist.
The Occupational Safety and Health Administration does not specifically set exposure limits for radium, and instead limits ionizing radiation exposure in units of roentgen equivalent man based on the exposed area of the body. Radium sources themselves, rather than worker exposures, are regulated more closely by the Nuclear Regulatory Commission, which requires licensing for anyone possessing 226Ra with activity of more than 0.01 μCi. The particular governing bodies that regulate radioactive materials and nuclear energy are documented by the Nuclear Energy Agency for member countries – for instance, in the Republic of Korea, the nation's radiation safety standards are managed by the Korea Radioisotope Institute, established in 1985, and the Korea Institute of Nuclear Safety, established in 1990 – and the IAEA leads efforts in establishing governing bodies in locations that do not have government regulations on radioactive materials.
Stimulants enhance the activity of the central and peripheral nervous systems. Common effects may include increased alertness, awareness, wakefulness, endurance, productivity and motivation, arousal, locomotion, heart rate and blood pressure, and a diminished desire for food and sleep. Use of stimulants may cause the body to reduce significantly its production of natural body chemicals that fulfill similar functions. Until the body reestablishes its normal state, once the effect of the ingested stimulant has worn off the user may feel depressed, lethargic, confused, and miserable. This state is referred to as a "crash", and may provoke reuse of the stimulant. Abuse of central nervous system (CNS) stimulants is common. Addiction to some CNS stimulants can quickly lead to medical, psychiatric, and psychosocial deterioration. Drug tolerance, dependence, and sensitization as well as a withdrawal syndrome can occur. Stimulants may be screened for in animal discrimination and self-administration models which have high sensitivity albeit low specificity. Research on a progressive ratio self-administration protocol has found amphetamine, methylphenidate, modafinil, cocaine, and nicotine to all have a higher break point than placebo that scales with dose indicating reinforcing effects. A progressive ratio self-administration protocol is a way of testing how much an animal or a human wants a drug by making them do a certain action (like pressing a lever or poking a nose device) to get the drug.
Neonicotinoids, such as imidacloprid, are synthetic insecticides derived from and structurally similar to nicotine. They are widely used in agriculture and veterinary medicine. Unlike traditional surface-applied nicotine pesticides, neonicotinoids are systemic: they are absorbed throughout the plant and cannot be washed off. This reduces worker exposure but requires timed applications to limit consumer residues in food crops.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
The lyophilized powder is commonly kept at -20 °C or lower, protected from moisture and light. Solutions may require colder storage and should avoid repeated freeze-thaw cycles. General peptide stability practices apply.